Tasquinimod

DRUG10 trials

Sponsors

Active Biotech AB, Andrew J. Armstrong, MD, Ipsen, Roswell Park Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Conditions

Advanced or Metastatic Gastric CarcinomaAdvanced or Metastatic Hepatocellular CancerAdvanced or Metastatic Ovarian CancerBone-only Metastatic Castration-Resistant Prostate Cancer (CRPC)Hormone-Resistant Prostate CancerMetastatic Castrate Resistant Prostate CancerMetastatic Prostate CarcinomaMetastatic Renal Cell Cancer

Phase 1

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

CompletedNCT01513733

Andrew J. Armstrong, MDProstate Cancer

Start: 2012-01-31End: 2016-06-30Updated: 2018-09-04

A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer

WithdrawnNCT02396368

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBone-only Metastatic Castration-Resistant Prostate Cancer (CRPC), Prostate Cancer

Start: 2015-03-31End: 2017-07-31Updated: 2015-11-20

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

TerminatedNCT04405167

University of PennsylvaniaMultiple Myeloma

Start: 2020-07-10End: 2025-07-01Updated: 2025-10-07

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

RecruitingNCT06327100

M.D. Anderson Cancer CenterPost-Essential Thrombocytosis Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Start: 2024-08-01End: 2031-05-01Target: 33Updated: 2026-05-26

Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition

RecruitingNCT06605586

Stichting Hemato-Oncologie voor Volwassenen NederlandMyelofibrosis

Start: 2025-02-20End: 2030-03-31Target: 20Updated: 2025-03-07

Phase 2

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

TerminatedNCT01732549

IpsenMetastatic Castrate Resistant Prostate Cancer

Start: 2013-01-31End: 2015-05-31Updated: 2019-11-22

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

CompletedNCT01743469

IpsenAdvanced or Metastatic Gastric Carcinoma, Advanced or Metastatic Hepatocellular Cancer, Advanced or Metastatic Ovarian Cancer +1

Start: 2012-12-31End: 2016-04-30Updated: 2019-01-08

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

CompletedNCT02159950

Roswell Park Cancer InstituteHormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma +1

Start: 2015-01-31Updated: 2023-04-27

Phase 3

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

CompletedNCT01234311

Active Biotech ABProstate Cancer

Start: 2011-03-31End: 2015-08-31Updated: 2015-10-21

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer

TerminatedNCT02057666

IpsenProstatic Neoplasms, Castration-Resistant

Start: 2014-01-31End: 2015-05-31Updated: 2021-04-23

Related Papers

IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma

Blood2025-11-03

Clinical activity of novel targeting of S100A9 with tasquinimod for relapsed and refractory multiple myeloma (RRMM).

Journal of Clinical Oncology2025-05-28

Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Blood2024-11-052 citations

Phase 1 study of tasquinimod, an S100A9 inhibitor, alone and in combination with IRd for relapsed and refractory multiple myeloma (RRMM).

Journal of Clinical Oncology2023-06-01

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma

Journal for ImmunoTherapy of Cancer2023-01-0118 citations

Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression <i>in Vitro</i>

Blood2021-11-052 citations

Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo

Blood2021-11-051 citations

A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma

Blood2020-11-044 citations

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer

JAMA Oncology2018-05-17100 citations

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.

2017-11-0121 citations

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers.

2017-10-0122 citations

Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC).

Journal of Clinical Oncology2017-05-205 citations

A Phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castration-resistant prostate cancer (mCRPC), secondary endpoints.

Journal of Clinical Oncology2016-01-105 citations

Phase Ib trial of cabazitaxel and tasquinimod in men with heavily pretreated metastatic castration resistant prostate cancer (mCRPC): The CATCH trial.

Journal of Clinical Oncology2016-01-103 citations

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.

Journal of Clinical Oncology2016-01-103 citations